NCT03688802: A reported trial by Oyster Point Pharma, Inc.
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03688802 |
|---|---|
| Title | A Single-Center, Randomized, Controlled, Masked Clinical Trial to Evaluate the Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation (The IMPERIAL Study) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 25, 2018 |
| Completion date | Sept. 30, 2019 |
| Required reporting date | Sept. 30, 2022, midnight |
| Actual reporting date | Sept. 10, 2021 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |